Cost of Clinical Trials: A Breakdown (Infographic)

What are the main costs of clinical trials, and why are they so expensive? Our team at Clinical Research IO searched the literature to find out how clinical trial costs differed by indication, and what the main cost drivers were.

Successful clinical development of a drug, from preclinical testing to marketing approval, requires a vast amount of resources and money. Drug development costs are on the rise, and pharmaceutical/biotechnology companies are seeking solutions for faster and cheaper development. These include repurposing approved drugs for new indications, and incorporating computational biology algorithms into preclinical tests for more efficient screening of molecules, among other methods. Running clinical trials is a major portion of drug development costs. What are the main costs of clinical trials, and why are they so expensive? Our team at Clinical Research IO searched the literature to find out how clinical trial costs differed by indication, and what the main cost drivers were. Check out the clinical trial cost breakdown below.

The evolving landscape of clinical trial software is poised to significantly reduce trial costs, and enable drugs/medical devices to come to market more quickly. If you are considering adopting eSource or CTMS technology for your trials, check out our solutions and request a demo to learn more.

Progress Notes are Vital to Source Data

Progress notes are free-text entries by the investigator, coordinator or study team member that are inserted into the source record. Generally, these play a critical and highly undervalued role in the study process. Progress notes are often used to: Clarify or confirm any data points that may appear as outliers, even before a query is...

Sponsors, Funding is Tight – Be Smart with Your Money

Getting a new product to market is expensive. There are a variety of studies and research that point to a wide array of costs, but generally speaking, it costs nearly $3 billion dollars to bring a new drug to market. Yes, you read that correctly. Beyond this, the success rate of a new compound to...

The FDA’s Decentralized Clinical Trials Draft Guidance Explained

The highly anticipated Decentralized Clinical Trials (DCT) draft guidance from the FDA was finally released on 02-May-2023. In this 19-page document, the FDA outlines its current thinking around the concept of DCTs. From the outset of the draft guidance, the FDA makes a clear point on what DCTs can mean for patients and the patient...